IP Library › Granted Patent US 11,084,800
Granted Patent B2
US 11,084,800 · App. 16/555,914 · Granted Aug 10, 2021

Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders

Inventors: Jason Allan Wiles (Madison, CT); Avinash S. Phadke (Branford, CT); Milind Deshpande (Madison, CT); Atul Agarwal (Hamden, CT); Dawei Chen (Guilford, CT); Venkat Rao Gadhachanda (Hamden, CT); Akihiro Hashimoto (Branford, CT); Godwin Pais (Hamden, CT); Qiuping Wang (Bethany, CT); Xiangzhu Wang (Branford, CT); Joel Charles Barrish (Richboro, CT); William Greenlee (New Haven, CT); Kyle J. Eastman (New Haven, CT)
Assignee: Achillion Pharmaceuticals, Inc.
C07D401/14C07D403/14C07D409/14C07D471/04C07D471/08C07D491/107C07D498/10C07F5/027
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,084,800
App. No.
16/555,914
Granted
Aug 10, 2021
Kind
B2
Abstract

Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

Claims (21)

1. A compound selected from:

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

8. The pharmaceutical composition of claim 7 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

9. The pharmaceutical composition of claim 7 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

10. The pharmaceutical composition of claim 7 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

11. The pharmaceutical composition of claim 7 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2019
From: WILES, JASON ALLAN; PHADKE, AVINASH S.; DESHPANDE, MILIND; AGARWAL, ATUL; CHEN, DAWEI; GADHACHANDA, VENKAT RAO; HASHIMOTO, AKIHIRO; PAIS, GODWIN; WANG, QIUPING; BARRISH, JOEL CHARLES; GREENLEE, WILLIAM; EASTMAN, KYLE J.
To: ACHILLION PHARMACEUTICALS, INC.
Reel/Frame 050484/0846 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2019
From: WANG, XIANGZHU
To: ACHILLION PHARMACEUTICALS, INC.
Reel/Frame 050484/0876 →
Continuity (4)
Continuation PCTUS2018020528 · Mar 1, 2018
Provisional Application 62465782 · Mar 1, 2017
Provisional Application 62466301 · Mar 2, 2017
Related Publication 20200071301A1 · Mar 5, 2020
Cited By (4)
US 12,239,645 US 12,297,205 US 12,338,230 US 12,479,856